ISIS PHARMACEUTICALS INC's ticker is ISIS and the CUSIP is 464330109. A total of 1 filers reported holding ISIS PHARMACEUTICALS INC in Q4 2011. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $353,000 | -30.5% | 8,742 | -1.1% | 0.01% | -28.6% |
| Q2 2015 | $508,000 | -8.8% | 8,835 | +1.1% | 0.01% | -12.5% |
| Q1 2015 | $557,000 | +1195.3% | 8,742 | +694.7% | 0.01% | +700.0% |
| Q3 2014 | $43,000 | -99.1% | 1,100 | -99.2% | 0.00% | -99.3% |
| Q2 2014 | $4,861,000 | +44.2% | 141,100 | +80.9% | 0.14% | +37.5% |
| Q1 2014 | $3,371,000 | -10.9% | 78,000 | -17.9% | 0.10% | -16.1% |
| Q4 2013 | $3,785,000 | +34.4% | 95,000 | +26.7% | 0.12% | +27.8% |
| Q3 2013 | $2,816,000 | +249.4% | 75,000 | +150.0% | 0.10% | +246.4% |
| Q2 2013 | $806,000 | +58.7% | 30,000 | 0.0% | 0.03% | +55.6% |
| Q1 2013 | $508,000 | -66.5% | 30,000 | -79.3% | 0.02% | -70.0% |
| Q4 2012 | $1,517,000 | +191.2% | 145,000 | +291.9% | 0.06% | +185.7% |
| Q3 2012 | $521,000 | +8.5% | 37,000 | -7.5% | 0.02% | 0.0% |
| Q2 2012 | $480,000 | -42.4% | 40,000 | -57.9% | 0.02% | -44.7% |
| Q1 2012 | $833,000 | +168.7% | 95,000 | +120.9% | 0.04% | +171.4% |
| Q4 2011 | $310,000 | – | 43,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BB BIOTECH AG | 7,202,585 | $270,385,000 | 14.71% |
| DOWLING & YAHNKE LLC | 675,798 | $25,369,000 | 3.98% |
| GARRISON BRADFORD & ASSOCIATES INC | 100,700 | $3,780,000 | 3.87% |
| WILLIAM HARRIS INVESTORS INC | 312,834 | $11,743,000 | 3.67% |
| Meditor Group Ltd | 490,000 | $18,395,000 | 2.59% |
| AVALON CAPITAL MANAGEMENT | 50,943 | $1,912,000 | 1.89% |
| Orinda Asset Management LLC | 14,665 | $551,000 | 1.73% |
| PINNACLE ASSOCIATES LTD | 2,064,760 | $77,511,000 | 1.60% |
| PERKINS CAPITAL MANAGEMENT INC | 52,850 | $1,984,000 | 1.43% |
| NCM Capital Advisers, Inc. | 24,950 | $937,000 | 1.04% |